UCSF Benioff Children's Hospital - Oakland
Locations
Transplant Summary
Overview
Established in January 2000, the BMT program at UCSF Benioff Children's Hospital Oakland provides a comprehensive range of pediatric and young adult transplant and cellular therapy services in the San Francisco Bay Area, including referrals throughout northern California, nationally and internationally. Our comprehensive services are available throughout the transplant trajectory of care and include donor evaluation, recipient evaluation, intra-transplant care, donor collection, post-transplant care in a pediatric and young adult outpatient facility, and photopheresis for acute and chronic graft versus host disease. The center has now also expanded its care giving by participating in transplantation clinical trials and commercial products for patients with hemoglobinopathies (e.g., sickle cell and thalassemia)This center has been performing allogeneic transplants since 2000 and has been an NMDP transplant center since June 2002.
Attending physicians
Adult - Nahal Lalefar, Mark Walters
Pediatric - Nahal Lalefar, Mark WaltersTransplants performed
Marrow/PBSC, single cord, and double cordCord blood transplants
Pediatric onlyOther programs and services
Comprehensive Sickle Cell Program
Comprehensive Thalassemia Program
Comprehensive Hematology & Oncology Program
Integrated Pediatric Palliative Care Program
Hospital-based school program
Child Life Services, Art Program & Music Therapy Program
HLA Laboratory
Gene therapy clinical trials
Gene therapy commercial products
Clinical Trials
Ronald McDonald Family Support ServicesPatient survival information for this center
This center's actual 1-year survival results are similar to the expected rate for this center*.The survival information we have for this center includes ONLY:- Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2020, 2021, 2022 and
- Who had their transplant at a U.S. transplant center, and
- Who had follow-up information provided by the transplant center for analysis
For this center, we have survival information for 29 patients.The actual 1-year survival of these patients is 93.1%.Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 79.2% and 99.7%.For help with understanding these statistics, please see Understanding Transplant Outcomes.For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report (Opens in a new tab) at bloodcell.transplant.hrsa.gov.* The expected survival rate for a transplant center can be below, similar to, or above the range listed. This is based on comparing patient survival at all centers that treated patients with similar diseases.
The survival rate cannot tell how you will do with your transplant. Talk to your doctor to understand your prognosis or the likely course of your disease.
Total pediatric transplants
56
Transplants reported by the centers (from January 1, 2022 to December 31, 2023)
Marrow PBSC Cord blood Total AllogeneicRelated donorMarrow8PBSC7Cord blood0Total15Unrelated donorMarrow6PBSC3Cord blood0Total9Total allogeneicMarrow14PBSC10Cord blood0Total24AutologousMarrowBoth marrow & PBSC 32PBSC—Cord blood—Total32Total combinedMarrowBoth marrow & PBSC 56PBSC—Cord blood0Total56All Diseases
Number of transplants by age reported from January 1, 2022 to December 31st, 2023(includes marrow, PBSC and cord blood)
0-18 19-44 45-64 65+ Total Related 0-181319-44245-64065+0Total15Unrelated 0-18719-44245-64065+0Total9Autologous 0-183219-44045-64065+0Total32Total 0-185219-44445-64065+0Total56Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.
Centers are not required to report autologous transplants so the numbers might be incomplete.
More information about transplants can be found:
- U.S. Transplant Data by Center (Opens in a new tab) report at blood cell.transplant.hrsa.gov
- List of diseases
Transplant center resources
NMDP patient navigators
Patient navigators can answer your questions about choosing a transplant center and provide support and education to help you throughout your transplant journey.
- Inside the United States: 1 (888) 999-6743
- Outside the United States: 1 (763) 406-3410. (Long distance or international charges may apply.)
Email: patientinfo@nmdp.org
More resources
- Choosing a transplant center
- Preparing for transplant
- Learn about transplant outcomes and treatment decisions (Opens in a new tab)
- Support and resources (including non-English materials)
- U.S. Transplant Data by Center (Opens in a new tab) at blood cell.transplant.hrsa.gov
Blood and Marrow Transplant Program
747 52nd Street Oakland, CA 94609 Phone:510-428-3374 For more information about this program: https://www.childrenshospitaloakland.org/main/departments-services/blood-marrow-transplantation-bmt-5.aspx (Opens in a new tab)Overview
HCT recipients return to Oakland (if possible) for annual evaluations around the anniversary of their transplant. Since many patients are being followed by their referring physicians, who may not have HCT transplantation experience, the patients are assessed for any signs or symptoms of graft-vs-host disease, endocrine dysfunction, disease status, and any post transplantation complications. If a recipient is not able to return Oakland, a BMT team member may communicate with the patient's current primary care physician to coordinate an evaluation in their local community. The process should ideally include review of evaluation results and provision of a summary of findings and recommendations to the family and primary care physician. The annual assessments are conducted with the neuro-oncology and general oncology teams, and with input by the pediatric oncology survivorship program in children with cancer. Patients with hemoglobin disorders are evaluated with input from the thalassemia and sickle cell disease programs.
Staff
Program Director:Mark Walters, MDProgram Coordinator:Sherrie Shiota, PA-CMedical Specialties in Program
Allergy/immunology, cardiology, dentistry, dermatology, endocrinology, gastroenterology, general surgery, hematology, hepatology, infectious disease, nephrology, neurology, oncology, ophthalmology/optometry, orthopedics, otolaryngology, palliative care, psychiatry/psychology, pulmonology, rheumatology, urology.Medical Services Offered
Chronic GVHD management, financial counseling, genetic counseling, nutrition/dietetics, occupational therapy, pain management, physical therapy and rehabilitation, social services, vaccinations.Telemedicine services are available.Patient Eligibility
Children- Allogeneic and Autologous transplant recipients
- 6 months after transplant.
- Patients who were transplanted as a child at this center up to age 30
- Does accept patients who were transplanted at another hospital
- Will admit pediatric patients who transferred into the program if they are under age 30
- Will accept adult patients who were transplanted as a child at another center up to age 30